Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

MARK ONE

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the Quarterly Period ended June 30, 2023; or

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from ________ to ________

WORLD HEALTH ENERGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		59-2762023
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

1825 NW Corporate Blvd. Suite 110, Boca Raton, FL		33431
(Address of principal executive offices)		Zip Code

(561) 870-0440

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 14, 2023, there were issued and outstanding 520,796,074,663 shares of the registrant’s common stock, par value $0.00001 per share, were outstanding.

WORLD HEALTH ENERGY HOLDINGS, INC.

Form 10-Q

June 30, 2023

	Page

PART I — FINANCIAL INFORMATION

Item 1 – Financial Statements – Unaudited	3

Condensed Consolidated Balance Sheets – June 30, 2023 and December 31, 2022	4

Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023 and 2022	5

Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three and six months ended June 30, 2023 and 2022	6

Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022	8

Notes to Condensed Consolidated Financial Statements	9

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3 – Quantitative and Qualitative Disclosures About Market Risk	27

Item 4 – Controls and Procedures	27

Item 1 – Legal Proceedings	28

Item 1A – Risk Factors	28

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds	29

Item 3 – Defaults upon Senior Securities	29

Item 4 – Mine Safety Disclosures	29

Item 5 – Other Information	29

Item 6 – Exhibits	29

Exhibit Index	29

SIGNATURES	30

WORLD HEALTH ENERGY HOLDINGS, INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF JUNE 30, 2023

(UNAUDITED)

WORLD HEALTH ENERGY HOLDINGS, INC .

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF JUNE 30, 2023

IN U.S. DOLLARS

(UNAUDITED)

TABLE OF CONTENTS

	Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:
Interim Condensed Consolidated Balance sheets	4
Interim Condensed Consolidated Statements of Comprehensive loss	5
Interim Condensed Consolidated Statements of stockholders’ equity	6
Interim Condensed Consolidated Statements of cash flows	8
Notes to Interim condensed consolidated financial statements	9 - 15

WORLD HEALTH ENERGY HOLDINGS, INC .

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS

(U.S. dollars except share and per share data)

	June 30, 2023			December 31, 2022
		(Unaudited)			(Audited)
Assets
Current Assets
Cash and cash equivalents		267,151			56,346
Accounts receivable, net		34,413			23,362
Prepaid share based payment to service providers		-			55,556
Related party		63,209			50,253
Other current assets		83,831			90,991
Total Current assets		448,604			276,508

Non-current assets
Right of use asset arising from operating lease		142,272			166,882
Long term prepaid expenses		22,521			23,679
Property and equipment, net		46,756			43,167
Funds in respect of employee rights upon termination		28,373			28,824
Investment in investee (Note 5)		152,766			-
Intangible assets		9,693,958			9,693,958
Total non-current assets		10,086,646			9,956,510

Total assets		10,535,250			10,233,018

Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable		135,379			107,979
Short term operating lease liability		56,432			57,971
Other current liabilities		472,830			621,733
Total current liabilities		664,641			787,683

Non-current Liabilities
Liability for employee rights upon retirement		196,834			180,066
Long term loan from parent company		2,012,339			2,012,339
Long term operating lease liability		69,133			96,102
Deferred tax liability		872,456			872,456
Total current liabilities		3,150,762			3,160,963

Total liabilities		3,815,403			3,948,646
Stockholders’ Equity
Series A preferred stock, par $0.0007, 10,000,000 shares authorized, 5,000,000 shares issued and outstanding as of June 30, 2023, and December 31, 2022		3,500			3,500
Preferred stock, value		3,500			3,500
Common stock, par $0.00001, 750,000,000,000 shares authorized as of June 30, 2023 and December 31, 2022. 520,796,074,663 and 516,302,741,330 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively		67,162,651			67,117,718
Additional paid-in capital		(36,194,050	)		(40,614,231	)
Treasury stock at cost – 20,000,000,000 shares of common stock		(8,000,000	)		(8,000,000	)
Accumulated other comprehensive loss		(9,095	)		(2,611	)
Accumulated deficit		(20,027,804	)		(16,035,848	)
Total Company’s stockholders’ equity		2,935,202			2,468,528
Non-controlling interests		3,784,645			3,815,844
Total stockholders’ equity		6,719,847			6,284,372
Total liabilities and stockholders’ equity		10,535,250			10,233,018

The accompanying notes are an integral part of the condensed consolidated financial statements.

WORLD HEALTH ENERGY HOLDINGS, INC .

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(U.S. dollars except share and per share data)

	2023			2022			2023			2022
	Six months ended						Three months ended
	June 30						June 30
	2023			2022			2023			2022
	(Unaudited)						(Unaudited)

Revenues		134,986			43,754			102,646			11,212

Research and development expenses		(1,005,123	)		(451,344	)		(502,187	)		(327,838	)
Selling and marketing expenses		(30,197	)		-			(3,527	)		-
General and administrative expenses		(3,132,840	)		(4,007,344	)		(1,148,382	)		(2,458,216	)
Operating loss		(4,033,174	)		(4,414,934	)		(1,551,450	)		(2,774,842	)
Finance income, net		15,503			36,634			10,614			33,338
Loss before equity in net loss of equity investments		(4,017,671	)		(4,378,300	)		(1,540,836	)		(2,741,504	)
Less: Equity in net gain (loss) of equity investments		(227	)		-			250			-
Net loss		(4,017,898	)		(4,378,300	)		(1,540,586	)		(2,741,504	)
Net loss attributable to non-controlling interests		25,942			-			12,930			-
Net loss attributable to the Company’s stockholders		(3,991,956	)		(4,378,300	)		(1,527,656	)		(2,741,504	)

Basic and diluted net loss per share		(0.00	)		(0.00	)		(0.00	)		(0.00	)
Basic net loss per share		(0.00	)		(0.00	)		(0.00	)		(0.00	)

Weighted average number of shares outstanding used in computing basic and diluted net loss per share		518,062,280,925			490,672,188,843			519,297,869,535			491,853,620,450
Weighted average number of shares outstanding used in computing basic and diluted net loss per share		518,062,280,925			490,672,188,843			519,297,869,535			491,853,620,450

Comprehensive loss:
Net loss		(4,017,898	)		(4,378,300	)		(1,540,586	)		(2,741,504	)
Other comprehensive loss - Foreign currency translation adjustments		(6,484	)		-			(4,211	)		-
Comprehensive loss		(4,024,382	)		(4,378,300	)		(1,544,797	)		(2,741,504	)
Net - loss attributable to non-controlling interests		25,942			-			12,930			-
Other comprehensive loss attributable to non-controlling interests		(5,257	)		-			(4,041	)		-
Comprehensive loss attributable to the Company’s stockholders		(4,003,697	)		(4,378,300	)		(1,535,908	)		(2,741,504	)

The accompanying notes are an integral part of the condensed consolidated financial statements.

WORLD HEALTH ENERGY HOLDINGS, INC .

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT

(U.S. dollars, except share and per share data)

	Number of Shares		Amount		Number of Shares		Amount		paid-in capital			account of shares			Treasury shares		Comprehensive Income			Accumulated deficit			equity (deficit)			Controlling Interest		equity (deficit)
	Series A Preferred Stock				Common Stock				Additional			Proceeds on					Accumulated Other						Total Company’s stockholders’			Non-		Total stockholders’
	Number of Shares		Amount		Number of Shares		Amount		paid-in capital			account of shares			Treasury shares		Comprehensive Income			Accumulated deficit			equity (deficit)			Controlling Interest		equity (deficit)

BALANCE AS OF DECEMBER 31, 2021		5,000,000		3,500		488,499,407,996		66,839,685		(62,263,494	)		-			-		(5,495	)		(6,093,450	)		(1,519,254	)		-		(1,519,254	)
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2022:
Issuance of shares		-		-		2,840,000,000		28,400		255,600						-		-			-			284,000			-		284,000
Share-based payment to employees and services providers		-		-		-		-		1,310,239						-		-			-			1,310,239			-		1,310,239
Proceeds on account of shares		-		-		-		-		-			290,000			-		-			-			290,000			-		290,000
Net loss		-		-		-		-													(1,636,796	)		(1,636,796	)		-		(1,636,796	)
BALANCE AS OF MARCH 31, 2022		5,000,000		3,500		491,339,407,996		66,868,085		(60,697,655	)		290,000			-		(5,495	)		(7,730,246	)		(1,271,811	)		-		(1,271,811	)
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED JUNE 30, 2022:
Issuance of shares		-		-		1,633,333,334		16,334		310,917			(40,000	)		-		-			-			287,250			-		287,250
Share-based payment to employees and services providers		-		-		30,000,000		300		2,457,605			-			-		-			-			2,457,905			-		2,457,905
Net loss		-		-		-		-													(2,741,504	)		(2,741,504	)		-		(2,741,504	)
BALANCE AS OF JUNE 30, 2022		5,000,000		3,500		493,002,741,330		66,884,719		(57,929,134	)		250,000			-		(5,495	)		(10,471,750	)		(1,268,160	)		-		(1,268,160	)

WORLD HEALTH ENERGY HOLDINGS, INC .

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(U.S. dollars, except share and per share data)

	Series A Preferred Stock				Common Stock				Additional			Proceeds on					Accumulated Other						Total Company’s stockholders ’			Non-			Total stockholders’
	Number of Shares		Amount		Number of Shares		Amount		paid-in capital			account of shares		Treasury shares			Comprehensive Income			Accumulated deficit			equity (deficit)			Controlling Interest			equity (deficit)

BALANCE AS OF DECEMBER 31, 2022		5,000,000		3,500		516,302,741,330		67,117,718		(40,614,231	)		-		(8,000,000	)		(2,611	)		(16,035,848	)		2,468,528			3,815,844			6,284,372
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2023:
Issuance of shares		-		-		1,640,000,000		16,400		512,600			-		-			-			-			529,000			-			529,000
Share-based payment to employees and services providers		-		-		-		-		2,219,109			-		-			-			-			2,219,109			-			2,219,109
Other comprehensive loss		-		-		-		-		-			-		-			(2,273	)					(2,273	)		(1,216	)		(3,489	)
Net loss		-		-		-		-													(2,464,300	)		(2,464,300	)		(13,012	)		(2,477,312	)
BALANCE AS OF MARCH 31, 2023		5,000,000		3,500		517,942,741,330		67,134,118		(37,882,522	)		-		(8,000,000	)		(4,884	)		(18,500,148	)		2,750,064			3,801,616			6,551,680
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED JUNE 30, 2023:
Issuance of shares		-		-		2,083,333,333		20,833		279,167			-		-			-			-			300,000			-			300,000
Issuance of shares for investment in an investee		-		-		770,000,000		7,700		146,300			-		-			-			-			154,000			-			154,000
Share-based payment to employees and services providers		-		-		-		-		1,263,005			-		-			-			-			1,263,005			-			1,263,005
Other comprehensive loss		-		-		-		-		-			-		-			(4,211	)					(4,211	)		(4,041	)		(8,252	)
Net loss		-		-		-		-													(1,527,656	)		(1,527,656	)		(12,930	)		(1,540,586	)
BALANCE AS OF JUNE 30, 2023		5,000,000		3,500		520,796,074,663		67,162,651		(36,194,050	)		-		(8,000,000	)		(9,095	)		(20,027,804	)		2,935,202			3,784,645			6,719,847

WORLD HEALTH ENERGY HOLDINGS, INC .

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. dollars except)

	2023			2022
	Six months ended
	June 30,
	2023			2022
	(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period		(4,017,898	)		(4,378,300	)
Adjustments required to reconcile net loss for the period to net cash used in operating activities:
Depreciation		8,574			4,930
Change in liability for employee rights upon retirement		17,219			(4,667	)
Equity in losses of non-consolidated entity		227			-
Share-based compensation expense		3,537,669			3,945,323
Change in operating lease liability		(3,898	)		(19,034	)
Change in accounts receivable		(11,051	)		(2,411	)
Change in other current assets		7,018			8,668
Change in accounts payable		27,399			12,438
Change in other accounts liabilities		(11,939	)		(50,120	)
Net cash used in operating activities		(446,680	)		(483,173	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Loans received from (granted to) related parties		(12,843	)		7,186
Loan to investee company					(10,000	)
Purchase of property and equipment		(12,163	)		(13,306	)
Net cash used in investing activities		(25,006	)		(16,120	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock		681,000			611,250
Proceeds on account of shares		-			250,000
Net cash provided by financing activities		681,000			861,250

Effect of exchange rate changes on cash and cash equivalents		1,491			-

INCREASE IN CASH AND CASH EQUIVALENTS		210,805			361,957

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		56,346			46,022

CASH AND CASH EQUIVALENTS AT END OF PERIOD		267,151			407,979

Supplemental disclosure of cash flow information:
Non cash transactions:
Investment in purchase of subsidiary	154,000	-
Issuance of share in exchange for debt	144,000	-

The accompanying notes are an integral part of the condensed consolidated financial statement

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL

Operations

World Health Energy Holdings, Inc. (the “Company” or “WHEN”) was formed on May 21, 1986 under the laws of the State of Delaware. The Company has invested in a variety of internally developed software programs that it strove to commercialize.

UCG, INC. (the “UCG”) was incorporated on September 13, 2017, under the laws of the State of Florida. The Company wholly-owns the issued and outstanding shares of RNA Ltd. (“RNA”).

RNA is primarily a research and development company that has been performing software design work for UCG in the field of cybersecurity under the terms of development agreement between UCG and RNA. UCG is primarily engaged in the marketing and distribution of cybersecurity-related products.

In anticipation of the transaction contemplated under the SG Merger Agreement, SG 77 Inc., a Delaware corporation and a wholly-owned subsidiary of UCG (“SG”), was incorporated on April 16, 2020 and all of the cybersecurity rights and interests held by UCG, including the share ownership of RNA, were assigned to SG.

SG Transaction

On April 27, 2020, the Company completed a reverse triangular merger pursuant to the Agreement and Plan of Merger (“SG Merger Agreement”) among the Company, R2GA, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Sub”), UCG, SG, and RNA. Under the terms of the SG Merger Agreement, R2GA merged with SG, with SG as the surviving corporation and a wholly-owned subsidiary of the Company (“SG Merger”). The SG Merger was effective as of April 27, 2020, whereby SG became a direct and wholly owned subsidiary of the Company and RNA became an indirect wholly owned subsidiary of the Company.

As consideration for the SG Merger, the Company issued 3,870,000 Series B convertible preferred stock, par value $0.0007 per share, to UCG. Each share of the Series B convertible preferred stock will automatically convert into 100,000 shares of common stock, par value $0.0007, for an aggregate amount of 387,000,000,000 shares of common stock, upon the filing with the Secretary of State of Delaware of an amendment to the Company’s certificate of incorporation increasing the number of authorized shares of common stock that the Company is authorized to issue from time to time.

On October 7, 2021, and following the approval by the stockholders, the Company increase its authorized shares to 750,000,000,000 (from 110,000,000,000 shares) and changed the par value of the common stock to $0.00001 (from $0.0007) (see Note 10).

Following the effectiveness of the Amendment referred to above, on December 3, 2021, the Company issued 387,000,000,000 shares of common stock to UCG upon the automatic conversion of all 3,870,000 outstanding Series B convertible preferred stock issued in April 2020 in connection with the acquisition of RNA from UCG.

The SG Merger was accounted for as a reverse asset acquisition. Under this method of accounting, SG was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the SG Merger: (i) SG’s stockholders owned a substantial majority of the voting rights in the combined company, (ii) SG designated a majority of the members of the initial board of directors of the combined company, and (iii) SG’s senior management holds all key positions in the senior management of the combined company. As a result of the reverse asset acquisition transaction, the shareholders of SG received the largest ownership interest in the Company, and SG was determined to be the “accounting acquirer” in the a reverse asset acquisition transaction.

As a result, the historical financial statements of the Company were replaced with the historical financial statements of SG. The number of shares prior to the reverse capitalization have been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer in the Recapitalization Transaction.

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL (continue)

CrossMobile Transaction

On March 22, 2022, the Company, CrossMobile Sp. z o.o, a company formed under the laws of Poland (“CrossMobile”) and the shareholders of CrossMobile (of which Mr. Giora Rosenzweig, held 40.67% and Mr. George Baumeohl held 3.33% of the issued preferred share capital of CrossMobile) entered into an Investment Agreement (“CrossMobile Agreement”) pursuant to which the Company is to purchase 26% of the outstanding common shares of CrossMobile on a fully diluted basis, in consideration of the issuance by the Company to CrossMobile of 10,000,000,000 restricted shares of the Company’s common stock (the “Initial Investment”).

On July 13, 2022, the Company issued 10,000,000,000 common shares with fair value of $4 million to Crossmobile to consummate the transaction.

CrossMobile is a licensed mobile virtual network operator in Poland, providing the necessary licenses and key infrastructure in the EU. With its involvement in CrossMobile, the Company expects to provide advanced cybersecurity solutions and other next-generation value-added services to CrossMobile’s future product offerings.

In addition, under the CrossMobile Agreement, the Company has the option, through January 22, 2024, to purchase additional shares of CrossMobile (“Additional Share Purchase Option”) such that following the additional purchase, the Company shall hold approximately 51% of CrossMobile’s outstanding common shares on a fully diluted basis. In the event the Company shall choose to exercise the option, the Company shall issue such number of restricted shares of common stock of the Company calculated based on pre-money valuation of CrossMobile as determined by an independent appraiser agreed between the Company and CrossMobile.

On October 25, 2022, the Company exercised the Additional Share Purchase Option (see Note 1C to the annual financial statements of 2022) and acquired the additional 25% shares of CrossMobile such that following the acquisition, the Company increased its holding from 26% to 51% of CrossMobile’s outstanding common stock on a fully diluted basis. In consideration for the exercise of the Additional Share Purchase Option, the Company issued 10,000,000 common stock on November 28, 2022 to Crossmobile.

The Company concluded that the acquired set of assets held at CrossMobile does not meet the definition of a business as substantially all the fair value of the gross assets is concentrated in the license held by CrossMobile. CrossMobile is at it start up stages and has no substantial operations. The only significant asset is the license which constitute more than 90% of the consideration paid.

The acquisition of the additional 25% constitute an asset acquisition in stages and resulted in obtaining control over all assets of CrossMobile and consolidating CrossMobile as of October 25, 2022.

The Company used the cost accumulation method to determine the cost of the acquisition. The Company used the carrying value of its 26% interest and did not recognize any gain or loss on the interest held at CrossMobile previously.

The consideration for the assets of CrossMobile was made through the issuance of 20,000,000,000 WHEN common shares with total fair value of $8 million ($0.0004 per share) and was issued to CrossMobile and not the shareholders of CrossMobile. Hence, upon obtaining control over all the assets of CrossMobile, the Company has gained control over its own shares held at CrossMobile. Based on the guidance in ASC 810-10-45-5, shares held by a subsidiary would not be considered outstanding and hence, the 20,000,000,000 common shares of the Company held by CrossMobile are presented as treasury shares in the consolidated balance sheet.

The assets acquisition of CrossMobile resulted in 49% noncontrolling interests in CrossMobile. The Company analogized from ASC 805-30-30-1 and added the fair value of the noncontrolling interests to the consideration paid for the assets acquired.

As described above the entire consideration paid by WHEN was with its shares, issued to CrossMobile. Based on the guidance in ASC 810-10-45-5 the shares are not considered outstanding. The Company concluded that the fair value of the consideration paid to be based on the fair value of the noncontrolling interests determined to be $7.9 million.

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL (continue)

Substantially all the consideration were allocated to the license, in addition to $0.9 million costs incurred in connection of the transaction, and hence the license was recognized at $8.8 million.

In addition, the Company recorded deferred tax liability and corresponding increase of the license value in an amount of $0.872 million, based on ASC 740-10-55-170 that accounts for situations when an asset is acquired outside of a business combination and the tax basis of the asset differs from the amount paid assuming tax basis of $0.

The Company, collectively with SG, RNA and CrossMobile are hereunder referred to as the “Group”.

InstaView Transaction

On January 26, 2023, the Company, InstaView Ltd. (“InstaView”) and the shareholder of InstaView entered into an Investment Agreement (the “InstaView Investment Agreement”) pursuant to which the Company purchased 26% of the outstanding common share capital of InstaView on a fully diluted basis, in consideration of the issuance by the Company to InstaView of 770,000,000 restricted shares of Company common stock. Under the InstaView Investment Agreement, subject to InstaView meeting annual revenues target specified in the Investment Agreement for each of the years ending December 31, 2023, 2024 and 2025, as certified by InstaView and its accountants and verified by the Company, the InstaView shareholder would be entitled to potentially up to an additional 230,000,000 shares of the Company’s common stock over this three year period (“contingent consideration”). As of the date of the transaction and as of the balance sheet date respectively, the Company estimates the fair value of the contingent consideration is zero.

In addition, under the InstaView Investment Agreement, the Company has the option to purchase additional shares of InstaView in each of calendar years 2023, 2024 and 2025, representing, in each such year, respectively, 7%, 8% and 10% of the share capital of InstaView for consideration consisting of, respectively, 207,307,692, 236,923,077 and 296,153,846 additional shares of the Company (“the Purchase Option”).

In connection with the InstaView Investment Agreement, the Company, InstaView and the InstaView shareholder also entered into a shareholders agreement pursuant to which the Company was granted standard preemptive rights, veto rights over certain corporate action by InstaView, restrictions on transfer of shares, rights of first offer and tag along rights. In addition, the InstaView shareholder undertook to not compete with InstaView for so long as he is an InstaView shareholder and for a three year period thereafter.

The Company determined the value of the 770,000,000 restricted shares of Company common stock issued to InstaView based on Company’s share price on the agreement date at $154,000 and recorded an equity investment assets in the balance sheet. As of the date of the transaction, the company allocated a total of $62,083 dollars out of this amount to the Purchase Option. The Purchase Option is presented according to a cost model. See also note 2 below as to Company’s accounting policy related to InstaView transaction.

Board and Shareholder Authority for Reverse Stock Split

On May 17, 2023, Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation (“Reverse Stock Split Certificate of Amendment”) in order to effect a reverse stock split of the Company’s common stock pursuant to a range of between 20,000-to-1 and 60,000-to-1 (the “Reverse Stock Split”), when and as determined by the Company’s Board of Directors. Pursuant to the Reverse Stock Split, each twenty thousand or sixty thousand shares of common stock, or any other figure within that range, as shall be determined by the Board of Directors at a later time, will be automatically converted, without any further action by the stockholders, into one share of common stock. The Reverse Stock Split Certificate of Amendment will be effective upon receipt of approval from the Financial Industry Regulatory Authority (“FINRA”) for the Reverse Stock Split and the filing with the Secretary of the State of Delaware. As of the date of this report, the Board of Directors has not determined any particular range for the Reverse Stock Split and no application has been presented to FINRA.

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL (continue)

Liquidity

Since inception, the Company has incurred losses and negative cash flows from operations. The Company has financed its operations mainly through fundraising from various investors.

The Group and George Baumeohl, a Company director, have entered into an investment agreement signed on November 1, 2022, where the director has committed to invest up to $3,000,000 through August 2025, as needed by the Company through the purchase of shares of the Company’s common stock. As of June 30, 2023 an amount of $625,000 out of the $3,000,000 was invested in the Company. See also note 3c.

Based on the projected cash flows considering the investment agreement, management is of the opinion that its existing cash will be sufficient to meet its obligations for a period longer than 12 months from the date of the approval of these consolidated financial statements..

Risk factors

The Group face a number of risks, including uncertainties regarding finalization of the development process, demand and market acceptance of the Group’s products, the effects of technological changes, competition and the development of products by competitors. Additionally, other risk factors also exist, such as the ability to manage growth and the effect of planned expansion of operations on the Group’s future results. In addition, the Group expects to continue incurring significant operating costs and losses in connection with the development of its products and increased marketing efforts. As mentioned above, the Group has not yet generated significant revenues from its operations to fund its activities, and therefore the continuance of its activities as a going concern depends on the receipt of additional funding from its current stockholders and investors or from third parties.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Unaudited Interim Financial Statements

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiary, prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions to Form 10-Q. In the opinion of management, the financial statements presented herein have not been audited by an independent registered public accounting firm but include all material adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the financial condition, results of operations and cash flows for the six-months ended June 30, 2023. However, these results are not necessarily indicative of results for any other interim period or for the year ended December 31, 2023. The preparation of financial statements in conformity with GAAP requires the Company to make certain estimates and assumptions for the reporting periods covered by the financial statements. These estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses. Actual amounts could differ from these estimates.

Certain information and footnote disclosures normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on published on the OTCIQ, for the year ended December 31, 2022.

Principles of Consolidation

The consolidated financial statements are prepared in accordance with GAAP. The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All inter-company balances and transactions have been eliminated.

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continue)

Use of Estimates

The preparation of unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, certain revenues and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates.

Investment in investee

The Company accounts of its options in InstaView in accordance with ASC 321, Investments – Equity Securities. The Company elected the measurement alternative under which the options are measured at cost as they have no readily determinable fair value. The carrying amount of the investment is included within Investment in investee, non-current assets in the Consolidated Balance Sheets. The equity securities will be carried at cost less impairment, if any, and subsequently measured to fair value upon observable price changes in an orderly transaction for the identical or similar investments with any gains or losses recorded to the consolidated statement of operations and comprehensive income

NOTE 3 – COMMON STOCK

On February 8, 2023, the Company entered into an investment agreement with a shareholder pursuant to which it raised $60,000 from the private placement of share of our common stock at a per share purchase price of $0.0003, in respect of which it issued to the shareholder to 200,000,000 shares of Common Stock.

On February 8, 2023, the Company issued to the investor specified in item 2 above and a designee an aggregate of 1,440,000,000 shares of common stock in satisfaction of a loan made by the shareholder to the Company in the principal amount of $120,000 plus interest of $24,000 of accrued interest, originally received for a period of 10-year.

On May 5, 2023 and on June 30, 2023, the Company issued to George Baumeohll, a director and a shareholder, an aggerate of 2,083,333,333 shares of common stock for aggregate subscription proceeds of $625,000 under the November 1, 2022, investment agreement with Mr. Baumeohll in respect of which he is entitled to shares of the Company’s common stock, at a per share price of $0.0003.

On May 15, 2023, the Company issued 770,000,000 shares of common stock as consideration under InstaView Transaction (see note 1D above).

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 - STOCK OPTIONS

The following table presents the Company’s stock option activity during the three and six months ended June 30, 2023:

SCHEDULE OF STOCK OPTION ACTIVITY

	Number of Options		Weighted Average Exercise Price
Outstanding at December 31,2022		46,600,000,000		0.001
Granted		2,000,000		0.001
Exercised		-		-
Forfeited or expired		-		-
Outstanding at March 31,2023		46,602,000,000		0.001
Granted		-		-
Exercised		-		-
Forfeited or expired		-		-
Outstanding at June 30,2023		46,602,000,000		0.001
Number of options exercisable at June 30, 2023		9,600,000,000		0.001

The aggregate intrinsic value of the awards outstanding as of June 30, 2023 is 0. These amounts represent the total intrinsic value, based on the Company’s stock price of $0.0001 as of June 30, 2023, less the weighted exercise price. This represents the potential amount received by the option holders had all option holders exercised their options as of that date.

The stock options outstanding as of June 30, 2023, have been separated into exercise prices, as follows:

Exercise price	Stock options outstanding		Weighted average remaining contractual life – years		Stock options vested
	As of June 30, 2023
0.001		46,602,000,000		3.26		17,525,000,000
		46,602,000,000		3.26		17,525,000,000

The stock options outstanding as of June 30, 2022, have been separated into exercise prices, as follows:

Exercise price	Stock options outstanding		Weighted average remaining contractual life – years		Stock options vested
	As of June 30, 2022
0.001		13,200,000,000		3.55		-
		13,200,000,000		3.55		-

Compensation expense recorded by the Company in respect of its stock-based compensation awards for the period of six months ended June 30, 2023 was $3,537,670 and are included in the Statements of Operations.

On January 26, 2023, RNA entered into two consulting agreements for the design of new generation of Internet Of Things (“IOT”) devices and for research and update of international needs of IOT devices with two consultants under which it undertook to issue to each of the consultant Non-Plan option to purchase 1,000,000,000 shares of the Company’s common stock at per share exercise price of $0.0002, exercisable over 4 years, of which options for 250,000,000 of the share will vest on each of the anniversaries of the execution of the agreement, beginning with January 24, 2024 and thereafter on each subsequent anniversary, subject to continued services with RNA. The fair value of both of the options was determined using the Black-Scholes pricing model at $563,230, assuming a risk free rate of 3.72%, a volatility factor of 186.71%, dividend yields of 0% and an expected life of 4 years. Total compensation expenses during the six months ended June 30, 2023 amounted to $110,006 and were recorded as share based compensation under research and development expenses.

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5 - EQUITY METHOD INVESTMENTS IN UNCONSOLIDATED AFFILIATES

The Company applies the equity method to investments when it has an ability to exercise significant influence over the operational decision-making authority and financial policies of the investee. During the six months ended June 30, 2023, the Company accounted for its 26% investments in InstaView as equity method investment from January 26, 2023.

The following tables summarize the carrying amounts, including changes therein, of our equity method investment in InstaView during the period:

SCHEDULE OF EQUITY METHOD INVESTMENT

	Six months ended June 30, 2023

Opening balance	$	-
Equity investment		91,917
Other comprehensive loss		(1,007	)
Equity losses		(227	)
Investments under equity method.		90,683
Purchased Option		62,083
Investment in investee as of June 30, 2023	$	152,766

NOTE 6 – RELATED PARTIES

SCHEDULE OF RELATED PARTY EXPENSES

Transactions and balances with related parties

	2023		2022		2023		2022
	Six months ended June 30				Three months ended June 30
	2023		2022		2023		2022
	(Unaudited)		(Unaudited)		(Unaudited)		(Unaudited)

General and administrative expenses:
Salaries and fees to officers		1,420,162		2,028,654		613,219		1,067,882
(*) of which share based compensation		1,329,597		1,943,090		573,520		1,023,625

Research and development expenses:
Salaries and fees to officers		137,213		69,723		59,402		46,308
(*) of which share based compensation		91,483		26,040		39,504		26,040

Balances with related parties and officers:

	As of June 30,		As of December 31,
	2023		2022
		(Unaudited)		(Audited)

Other current assets		63,209		50,253
Other accounts liabilities		103,311		-
Liability for employee rights upon retirement		123,723		229,167
Long term loan from related party (*)		2,012,339		2,012,339

(*)	Received from UCG by December 31, 2021. The loan bears no interest.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

The following discussion should be read in conjunction with the financial statements and related notes contained elsewhere in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2023. Certain statements made in this discussion are “forward-looking statements” within the meaning of the private securities litigation reform act of 1995,. These statements are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by the Company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used herein, the words “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks relating to the Company’s business, industry, and the Company’s operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report.

Overview

World Health Energy Holdings (“WHEN” or the “Company” or “us” ) is primarily engaged in the cybersecurity technology field. On April 27, 2020, WHEN completed a reverse triangular merger pursuant to the Merger Agreement among the Company, R2GA, UCG, SG, and RNA. Under the terms of the Merger Agreement, R2GA merged with and into SG, with SG remaining as the surviving corporation and a wholly-owned subsidiary of the Company. The Merger became effective as of April 27, 2020. Each of Gaya Rozensweig and George Baumeohl, directors of the Company, are also the sole shareholders and directors of UCG.

RNA is primarily a research and development company that has been performing software design services in the field of cybersecurity. SG is primarily engaged in the marketing and distribution of cybersecurity related products. In anticipation of the transaction contemplated under the Merger Agreement, SG was formed and all of the cybersecurity rights and interests held by UCG, including the share ownership of RNA, were assigned to SG.

Following the closing, each of SG 77 and RNA became wholly-owned subsidiaries of the Company.

Acquisition of CrossMobnile

On March 22, 2022 the Company, CrossMobile Sp z o.o., a company formed under the laws of Poland (“CrossMobile”) and the shareholders of CrossMobile (of which our CEO, Giora Rosenzweig, holds 40.67% and George Baumeohl, a director, holds 6.67%, of the issued preferred share capital of CrossMobile), entered into an Investment Agreement (the “Agreement”) pursuant to which the Company purchased in July 2022 an initial 26% equity stake of the outstanding common share capital of CrossMobile on a fully diluted basis, in consideration of the issuance by the Company to CrossMobile of 10,000,000,000 restricted shares of Company . In addition, for 18 months following the date of the Agreement, the Company has the option to purchase additional shares of CrossMobile, (the “Additional Share Purchase Option”), such that following such additional purchase, the Company shall hold approximately 51% of CrossMobile’s outstanding share capital on a fully diluted basis. On October 25, 2022, the Company exercised the Additional Share Purchase Option to acquire such additional shares of CrossMobile and the Company now holds approximately 51% of CrossMobile’s outstanding share capital on a fully diluted basis and proportionally voting rights. In consideration for the exercise of the Additional Share Purchase Option, the Company issued to CrossMobile an additional 10,000,000 shares of the Company’s common stock.

CrossMobile provides public mobile telephone services in Europe, (without its own radio infrastructure) We believe that the acquisition of CrossMobile provides an opportunity in our evolution and provides us with a strong foothold in the European mobile telecom market.. CrossMobile is planning to roll-out a comprehensive suite of value-added services for B2B and B2C customers in the telecom industry.

With our involvement in CrossMobile, we expect to provide advanced cybersecurity solutions and other next-generation value-added services to CrossMobile’s future product offerings.

The global telecom services market size was valued at USD 1,805.61 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2023 to 2030 ¹. The global cyber security market size is projected to grow from $172.32 billion in 2023 to $424.97 billion in 2030, at a CAGR of 13.8%². By combining the telecom focus with our existing cyber security product offering, our plan is to bring to market a new standard of service in value added telecom and security solutions for B2B and B2C customers alike.

During the six months ended June 30, 2023, CrossMobile accomplished the following

	a.	Be in the air with standard packages of Voice, SMS and Data in Poland and International Roaming.
	b.	Commence initial sales business customers of standard packages of Voice, SMS and Data in Poland and International Roaming that will generate first invoice in July 2023
	c.	Due to the need of focusing on sales, technical issues and corporate governance we postponed until Q3 to fully Initiate cooperation with existing or build new Telecom operators similar to CrossMobile to fully optimize ROI on the investment made in people and IT Systems. Focus areas will be USA, UK, Asia Pacific and selected countries in Europe with high potential.

Acquisition of Instaview

On Feb. 26, 2023 we completed the acquisition of an initial 26% of Instaview Ltd. (“Instaview”), an emerging technology company in the field of AI-based image processing systems, thermal cameras, home and enterprise security, livestock tracking and control appliances plus much more.

Instaview is engaged in the field of image processing systems and thermal cameras. Over the past 18 years, Instview has provided innovative security and managing solutions in hundreds of projects in Israel and overseas.

We believe that there is synergy between Instaview and our activities and marks the beginning of the revolution of the home and enterprise security market, which is estimated to be $120 billion in 2022 and projected to grow at a compound annual growth rate of 8% through 2030.”

1 Grand View Research, from https://www.grandviewresearch.com/industry-analysis/global-telecom-services-market

2 https://www.fortunebusinessinsights.com/industry-reports/cyber-security-market-101165

Combined WHEN Product Offerings

Our product offerings are comprised of three complementary segments, namely

	1.	Cyber Care, which is the long standing and core business segment of WHEN
	2.	AI based image processing systems such as audio-video systems and security cameras solutions being an off-line extension of the on-line Cyber Care services entered through the acquisition of 26% shares in Instaview
	3.	Mobile telecom GSM which is a new business segment, linking the off and on line business segments entered through the recent acquisition of CrossMobile

All three are targeting commercial enterprises (B2B) and individual users (B2C).

Cyber Care

B2B Offerings—Our B2B Cybersecurity system software development and implementation program focuses on developing a threat management software that provides innovative solutions for the constantly evolving cyber challenges of businesses, non-governmental organizations (NGO’s) and governmental entities.

In 2021 we launched OTOGRAPH, our comprehensive cybersecurity and information security system, to enable business enterprises to monitor, analyze and prevent suspicious or harmful behavior on corporate networks and connected devices. The OTOGRAPH is designed to analyze and prevent internal or external abuse or abnormal activity on enterprise devices, such as PCs, mobile phones, servers or any other operating system (OS)-based Internet of things (IOT) devices. IoT devices are the nonstandard computing devices that connect wirelessly to a network and have the ability to transmit data.

The rapid transition to open and cloud-based remote workforce has exposed businesses and organizations across the world to higher risks of cyber-attacks and information security breaches. To enable businesses to better protect their data and workflow, we developed a Business Behavioral Analysis (BBA) system that enables business leaders to track all activity from any given location on a one-stop dashboard. Developed over the past two years, OTOGRAPH provides aggregated data and a wide variety of real-time analytics such as real time monitoring of online behavior, applications and system behavior, data breaches, internal and external connections analytics, productivity analysis and psycholinguistic analysis. Corporations and organizations can then use the dashboard to detect suspicious human or device activities that put their company at risk.

OTOGRAPH was developed based on based on a state of the art intelligence technology combined with AI technology that processes and analyzes massive amounts of behavioral and communication data and enables organizations to make real time accurate preventive assessments and decisions to protect company assets and ensure operational efficiency. OTOGRAPH deploys a unique Business Behavioral Analysis (BBA) machine learning software. Behavioral digital data is extracted from all endpoint devices that are connected to the company’s network infrastructure – whether physically, wirelessly or remotely. The data is processed and analyzed to learn and to reveal the unique digital behavioral pattern of the organization as a whole and of every endpoint or individual.

OTOGRAPH then sets baselines of normal patterns for each, and constantly searches for anomalies – deviations from those expected patterns. The anomalies are detected automatically and instantly, categorized by their type and generate push alerts which are sent to the business leader’s dashboard and enabling him to respond to the threat.

OTOGRAPH is continuously learning and calibrating the normal patterns and their thresholds to minimize the number of false alarms and constantly adapt to the changing needs of organizations in real time. Our B2C Cybersecurity division targets families concerned with external cyber threats and exposures in addition to monitoring a child’s behavioral patterns that may alert parents to potential tragedies caused by cyber bullying, pedophiles, other predators, and depression.

B2C

SG’s Parental System offers a comprehensive solution which is designed to enable parents wishing to observe their children’s online behavior to learn if they are accessing inappropriate websites and content and/or to protect them from a range of threats including cyberbullying, pedophiles and other predators and identity theft.

The Parental System line is positioned as the “ultimate parental cyber solution”. This system incorporates a range of features enabling parents to view and manage their children’s Android phones and devices. The key elements of our proprietary solutions include the following: analysis of all incoming and outgoing written data; analysis of all incoming and outgoing audio communication; real time location tracking; environmental surroundings analysis; and cyber activity analysis.

The Parental System has similar features to those of the B2B yet tailored to fit the needs of parents and guardians to protect their children. Such variations focus on online behavioral patterns whether vocally, via short message service (“SMS”) or social media platforms. If there is a change in behavior patterns, the product is designed to immediately send the parent or adult guardian an alert. For example, as stated in several international reports, one of the identifiable indicators before suicide is social withdrawal, something which today appears as a significant decrease in text message exchanges. The system categorizes this decrease as a red flag. Moreover, there are certain words and phrases which increase in use prior to suicide which the system will detect these it will put them in the red flag category.*

* https://www.mayoclinic.org/healthy-lifestyle/tween-and-teen-health/in-depth/teen-suicide/art-20044308

While analyzing voice calls based on; tone of speech, lengths of the conversation and the frequency of calls, Parental System Analytics is capable of identifying changes in behavioral patterns and flagging these changes. For example, studies showed that with deteriorating mental health, the frequency of calls decreases and the sentences along with the length of the conversations get shorter. Any such discrepancy in behavior patterns will send a real time alert to the parent or legal guardian, potentially avoiding a tragedy.

Strategy Cyber Care: We believe that the technology underlying our product offering is our primary competitive advantage. The strength of our solution is driven by several proprietary technologies and methodologies that we have developed, coupled with how we have combined them into our highly versatile platform incl. the mobile telecom platform discussed below. These advantages enable our end users to

	●	Prevent trade secret and data leakage;

	●	Protect against hackers;

	●	Minimize loss of productivity;

	●	Detect embezzlements and thefts;

	●	Defend employees from harassments;

	●	Prevent talent and client poaching;

	●	Avoid human errors;

	●	Develop a new level of decision-making ability based on accurate and real-time data; and

	●	Assist parents and legal guardians in monitoring their minor children’s’ cyber online activities.

The Company’s go-to-market strategy focuses principally on generating revenue from software, services and licensing. The Company intends to drive revenue growth and to achieve margins that are consistent with those of other enterprise software companies.

We currently intend to sell substantially all of our products and services to distributors and resellers, which will sell to end-user customers, which we refer to in this report as our customers.

The implementation of our strategies is subject to our raising significant cash resources, of which no assurance can be provided that we will be successful in raising the needed capital on commercially reasonable terms. As of the date of this prospectus, we have no commitments for any capital raise.

Mobile telecom GSM

Following the first step, our next planned strategy is to add the advanced B2B and B2B Cyber Care bundled with the audio-video systems and security cameras solution and offer them as an integrated part of our GSM solutions. This will give our B2B the possibility to use the AI and BBA as a tool to increase not only security but as well efficiency in sales organizations where soft skills, emotions and personal relations are crucial.

In respect to the B2C market our strategy is to give families a tool to protect their assets and entire households in particular kids or pets and evenelderly members being fragile newcomers in the world of e-commerce, on-line banking and on-line dating.

The third step expected to be initiated in Q3 2023 in is to copy and paste the same scenario of combining Cyber Care and Mobile Telecom to other selected markets in North Africa, the USA and Europe.

To execute this strategy CrossMobile has engaged with not only telecom industry experts but as well high level sales experts from international FMCG sector that is expected to bring a new standard of cross selling and customer experience to the telecom market

Comparison of the Three Months Ended June 30, 2023 to the Three Months Ended June 30, 2022

Summary of Results of Operations

	Three months ended
	June 30
	2023			2022

Revenues	$	102,646			11,212
Operating Expenses
Research and development expenses		(502,187	)		(327,838	)
Selling and marketing expenses		(3,527	)		-
General and administrative expenses		(1,148,382	)		(2,458,216	)
Operating loss		(1,551,450	)		(2,774,842	)
Financing income, net		10,614			33,338
Loss before equity in net loss of equity investments		(1,540,836	)		(2,741,504	)
Less: Equity in net loss of equity investments		250			-
Net loss		(1,540,586	)		(2,741,504	)
Net loss attributable to non-controlling interests		12,930			-
Net loss attributable to the Company’s stockholders		(1,527,656	)		(2,741,504	)

Revenues

Our total revenue consists of sales of our products and services.

Operating Expenses

Our current operating expenses consist of three components - research and development expenses, selling and marketing expenses and general and administrative expenses.

Research and Development Expenses, net

We expect to continue incurring substantial expenses for the next several years as we continue to develop our product lines. We are unable, with any certainty, to estimate either the costs or the timelines in which those expenses will be incurred. The design and development activities will consume a large proportion of our current, as well as projected, resources.

Our research and development costs include costs are comprised of:

● internal recurring costs, such as personnel-related costs (salaries, employee benefits, equity compensation and other costs), materials and supplies, facilities and maintenance costs attributable to research and development functions; and

● fees paid to external parties who provide us with contract services, such as preclinical testing, manufacturing and related testing and clinical trial activities.

The following table discloses the breakdown of research and development expenses:

	Three Months Ended June 30
	2023		2022
Salaries and related expenses	$	111,339		88,022
Share-based compensation expenses		349,867		208,321
Subcontractors and other development costs		5,887		7,251
Depreciation and amortization		4,305		9,970
Rent and office maintenance		24,465		1,870
Other expenses		6,324		12,405
Total	$	502,187		327,838

Selling and Marketing Expenses

Selling and marketing expenses consist primarily of salaries and related expenses, professional services and other expenses.

The following table discloses the breakdown of selling and marketing expenses:

	Three Months Ended June 30
	2023		2022
Professional services		3,527		-
Total	$	3,527		-

We expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts in 2023 following the acquisition of Cross Mobile and our efforts to be in the air with standard packages of Voice, SMS and Data in Poland and International Roaming and initiate cooperation with existing or build new Telecom operators.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related expenses, professional services, rent and office maintenance and other non-personnel related expenses.

The following table discloses the breakdown of general and administrative expenses:

	Three Months Ended June 30
	2023		2022
Salaries and related expenses	$	55,477		63,089
Share-based compensation expenses		975,319		2,310,512
Professional services		86,067		30,357
Rent and office maintenance		16,346		30,153
Other expenses		15,173		24,105
Total	$	1,148,382		2,458,216

Revenues

Revenues for the three months ended June 30, 2023 and 2022 were $102,646 and $11,212, respectively. The increase in our revenues resulted primarily from services provided under a development agreement in an amount of $90,000 recognized during the three months ended June 30, 2023.

Research and Development Expenses. Research and development expenses consist of salaries and related expenses, share-based compensation expenses, consulting fees, service providers’ costs and overhead expenses. Research and development expenses increased from $327,838 during the three months ended June 30, 2022 to $502,187 during the three months ended June 30, 2023. The increase resulted primarily from increase in non-cash share-based compensation expenses, salaries and related expenses and in rent and maintenance costs partially offset by decrease in and depreciation costs associated with our development activities.

Selling and Marketing Expenses. Selling and marketing expenses consist primarily of professional fees. Selling and marketing expenses for the three months ended June 30, 2023 amounted to $3,527 as compared to $0 for the three months ended June 30, 2022. The increase is primarily attributable to expenses incurred in connection with the purchase of 51% of CrossMobile, which we completed in November 2022.

General and Administrative Expenses. General and administrative expenses consist primarily of salaries and related expenses, share-based compensation expenses and other non-personnel related expenses such as legal expenses. General and administrative expenses decreased from $2,458,216 for the three months ended June 30, 2022 to $1,148,382 in the three months ended June 30, 2023. The decrease is primarily attributed to the decrease in non-cash share-based compensation expenses partially offset by increase in professional services.

Financing Income, Net. Financing income, net decreased from $33,338 of financing income for the three months ended June 30, 2022 to financing income, net of $10,614 for the three months ended June 30, 2023. The decrease is mainly a result of currency exchange differences between the Dollar and the New Israeli Shekel.

Net Loss. As a result of the foregoing, our net loss for the three months ended June 30, 2023 was $1,540,586 compared to $2,741,504 for the three months ended June 30, 2022.

Comparison of the six Months Ended June 30, 2023 to the six Months Ended June 30, 2022

Summary of Results of Operations

	Six months ended
	June 30
	2023			2022

Revenues	$	134,986			43,754
Operating Expenses
Research and development expenses		(1,005,123	)		(451,344	)
Selling and marketing expenses		(30,197	)		-
General and administrative expenses		(3,132,840	)		(4,007,344	)
Operating loss		(4,033,174	)		(4,414,934	)
Financing income, net		15,503			36,634
Loss before equity in net loss of equity investments		(4,017,671	)		(4,378,300	)
Less: Equity in net loss of equity investments		(227	)		-
Net loss		(4,017,898	)		(4,378,300	)
Net loss attributable to non-controlling interests		25,942			-
Net loss attributable to the Company’s stockholders		(3,991,956	)		(4,378,300	)

Revenues

Our total revenue consists of sales of our products and services.

Operating Expenses

Our current operating expenses consist of three components - research and development expenses, selling and marketing expenses and general and administrative expenses.

Research and Development Expenses, net

Our research and development costs include costs are comprised of:

● fees paid to external parties who provide us with contract services, such as preclinical testing, manufacturing and related testing and clinical trial activities.

The following table discloses the breakdown of research and development expenses:

	Six Months Ended June 30
	2023		2022
Salaries and related expenses	$	173,683		176,099
Share-based compensation expenses		750,391		208,321
Subcontractors and other development costs		14,719		17,200
Depreciation and amortization		8,573		23,945
Rent and office maintenance		47,089		19,384
Other expenses		10,667		6,395
Total	$	1,005,123		451,344

Selling and Marketing Expenses

Selling and marketing expenses consist primarily of salaries and related expenses, professional services and other expenses.

The following table discloses the breakdown of selling and marketing expenses:

	Six Months Ended June 30
	2023		2022
Professional services		30,197		-
Total	$	30,197		-

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related expenses, professional services, rent and office maintenance and other non-personnel related expenses.

The following table discloses the breakdown of general and administrative expenses:

	Six Months Ended June 30
	2023		2022
Salaries and related expenses	$	149,916		129,049
Share-based compensation expenses		2,821,682		3,737,003
Professional services		106,409		57,134
Rent and office maintenance		47,200		46,473
Other expenses		7,633		37,685
Total	$	3,132,840		4,007,344

Revenues

Revenues for the six months ended June 30, 2023 and 2022 were $134,986 and $43,754, respectively. The increase in our revenues resulted primarily from services provided under a development agreement in an amount of $90,000 recognized during the three months ended June 30, 2023.

Research and Development Expenses. Research and development expenses consist of salaries and related expenses, share-based compensation expenses, consulting fees, service providers’ costs and overhead expenses. Research and development expenses increased from $451,344 during the six months ended June 30, 2022 to $1,005,123 during the six months ended June 30, 2023. The increase resulted primarily from increase in non-cash share-based compensation expenses and in rent and maintenance costs partially offset by decrease in salaries and related expenses and depreciation costs associated with our development activities.

Selling and Marketing Expenses. Selling and marketing expenses consist primarily of professional fees. Selling and marketing expenses for the six months ended June 30, 2023 amounted to $30,197 as compared to $0 for the six months ended June 30, 2022. The increase is primarily attributable to expenses incurred in connection with the purchase of 51% of CrossMobile, which we completed in November 2022.

General and Administrative Expenses. General and administrative expenses consist primarily of salaries and related expenses, share-based compensation expenses and other non-personnel related expenses such as legal expenses. General and administrative expenses decreased from $4,007,344 for the six months ended June 30, 2022 to $3,132,840 in the six months ended June 30, 2023. The decrease is primarily attributed to the increase in non-cash share-based compensation expenses partially offset by increase in professional services, salaries and related expenses and other non-personnel related expenses.

Financing Income, Net. Financing income, net decreased from $36,634 of financing for the six months ended June 30, 2022 to financing income, net of $15,503 for the six months ended June 30, 2023. The decrease is mainly a result of currency exchange differences between the Dollar and the New Israeli Shekel.

Net Loss. As a result of the foregoing, our net loss for the six months ended June 30, 2023 was $4,017,898 compared to $4,378,300 for the six months ended June 30, 2022.

Financial Condition, Liquidity and Capital Resources

Liquidity is the ability of an enterprise to generate adequate amounts of cash to meet its needs for cash requirements. At June 30, 2023 and December 31, 2022, we had current assets of $448,604 and $276,508, respectively, and total assets of $10,535,50 and $10,233,018 respectively. The increase in total assets is mainly due to the increase in intangible assets attributable to the purchase of 26% of the issued and outstanding shares of InstaView. We had current liabilities of $664,641 as compared to $787,683 as of June 30, 2023 and December 31, 2022, respectively and total liabilities of $3,815,403 as compared to $3,948,646 as of June 30, 2023 and December 31, 2022, respectively.

At June 30, 2023, we had a cash balance of $267,151 compared to the cash balance of $56,346 as of December 31, 2022. We have no cash equivalents.

At June 30, 2023, we had a negative working capital of $216,037 as compared with a working capital deficiency of $511,175 at December 31, 2022.

In November 2022, we entered into an investment agreement with George Baumeohl, our director, pursuant to which Mr. Baumeohl has agreed to support our operation by way of an equity investment of up to $3 million through August 2025, as needed. The agreement provides for sales of our common stock to Mr. Baumeohl at per share purchase prices ranging between $0.0003 and $0.0005. Through June 30, 2023, we have received an aggregate of $625,000 from Mr. Baumeohl in respect of which we issued to him in May and June 2023 2,083,333,333 shares of our common stock at a share price of $0.0003.

In addition, in February 2023, the Company issued to an investor and a designee an aggregate of 1,440,000,000 shares of common stock in satisfaction of a loan made by the investor to the Company in the principal amount of $120,000 plus interest of $24,000 of accrued interest for the 10-year loan period.

Management believes that funds on hand, as well as the subscription proceeds that we are to receive on a periodic basis under the committed subscription agreements with our director, will enable us to fund our operations and capital expenditure requirements through the next twelve months. Our requirements for additional capital during this period will depend on many factors.

We may seek to raise any necessary additional capital through a combination of private or public equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights, future revenue streams, or product c,andidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through private or public equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

Critical Accounting Policies

The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In preparing the consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated balance sheets and consolidated statements of operations. Actual results may differ significantly from those estimates.

While our significant accounting policies are described in more detail in the notes to our audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.

Off-Balance Sheet Arrangements We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures.

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported as specified in the SEC’s rules and forms and that such information required to be disclosed by us in reports that we file under the Exchange Act is accumulated and communicated to our management, including our Interim Chief Executive Officer, to allow timely decisions regarding required disclosure. Management, with the participation of our Interim Chief Executive Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures as of June 30, 2023. Based on that evaluation, our management, including our Chief Executive Officer, concluded that our disclosure controls and procedures were not effective as of June 30, 2023.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As disclosed in Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2022, our management concluded that our internal control over financial reporting was not effective at December 31, 2022. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. The limitation of the Company’s internal control over financial reporting was due to the applied risk-based approach which is indicative of many small companies with limited number of staff in corporate functions. The identified weakness were:

●	Material Weakness – We did not maintain effective controls over certain aspects of the financial reporting process because we (i) lacked a sufficient complement of personnel with a level of accounting expertise and an adequate supervisory review structure that is commensurate with our financial reporting requirements and (ii) we lacked controls over the disclosure of our business operations.

●	lack of segregation of duties Significant Deficiencies – Inadequate segregation of duties.

Our management believes the weaknesses identified above have not had any material effect on our financial results.

We expect to be materially dependent upon third parties to provide us with accounting consulting services for the foreseeable future which we believe will mitigate the impact of the material weaknesses discussed above. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP and establish an audit committee and implement internal controls and procedures, there are no assurances that the material weaknesses and significant deficiencies in our disclosure controls and procedures will not result in errors in our financial statements which could lead to a restatement of those financial statements.

Changes in Internal Controls over Financial Reporting.

Except for the material weakness noted above, there have been no changes in our internal control over financial reporting during the fiscal quarter ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

On October 27, 2020 WHEN filed suit in State Court, Palm Beach County, Florida, against FSC Solutions, Inc. (“FSC”), Eli Gal Levy (“EL”) and Padem Consultants Sprl (collectively, the “Defendants”). The suit relates to the Stock Purchase Agreement entered into by WHEN with FSC and its shareholders, which included EL, pursuant to which WHEN acquired all of the issued and outstanding stock of FSC in exchange for the issuance of 70 billion shares of WHEN unregistered common stock. FSC was the putative owner of a software and trading platform which WHEN intended to use to enter into the on-line trading business. Subsequent to the completion of the acquisition, we determined that FSC did not have control over the trading platform and software we expected to acquire and operate. The suit seeks declaratory judgment to unwind the FSC transaction and cancel the shares of WHEN common stock issued in the FSC transaction that are still outstanding.

A hearing was set for January 6, 2021 whereupon mediation was ordered. Mediation meetings were held but no resolution was reached. The Florida lawsuit is currently pending.

On or about, January 19, 2022, EL filed a lawsuit in the Delaware Court of Chancery seeking to remove the restrictive legend from all the shares of Common Stock held by EL (the “2022 Lawsuit”), which are approximately 23,000,000,000 shares. The Company retained the services of Delaware counsel and has moved to dismiss or stay the 2022 Lawsuit in favor of the previously filed Florida lawsuit, which involves the same parties and same issues. The Company’s motion is currently pending in the Delaware Court of Chancery.

On June 24, 2022 the Company filed an amended complaint in Palm Beach County, Florida (CASE NO. 50-2020- CA-011735), alleging violation of Fla. Stat. 517.301, seeking declaratory relief with regard to the status of the shares held and transferred by EL, and seeking a temporary injunction with regard to the transfer of any subject shares. EL answered the complaint and a hearing has been set for September 12, 2023.

The Company intends to continue to vigorously pursue this action and avail itself of all options lawfully available to it.

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not aware of any such legal proceedings or claims against us.

ITEM 1A. RISK FACTORS

An investment in the Company’s Common Stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on April 17, 2023, in addition to other information contained in our reports and in this quarterly report in evaluating the Company and its business before purchasing shares of our Common Stock. There have been no material changes to our risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2022.

ITEM 2. UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS

(i) On May 15, 2023, the Company issued 770,000,000 shares of common stock as consideration under InstaView Transaction.

(ii)In May 2023, the Company received subscription proceeds of $150,000 under the investment agreement with Mr. Baumeohll in respect of which in respect of which in respect of which in May 2023 the Company issued in May 2023 to Mr. Baumeohl 500,000,000 shares of Common Stock.[ David – I don’t get this one? Why not 1,583,333,333]

(iii) In June 2023, the Company received subscription proceeds of $150,000 under the investment agreement with Mr. Baumeohll in respect of which in respect of which in respect of which in May 2023 the Company issued in May 2023 to Mr. Baumeohl 500,000,000 shares of Common Stock

We relied upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”) by virtue of Section 4(a)(2) thereof and/or Regulation S promulgated by the SEC under the Act with respect to the issuance of such securities.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION:

None

ITEM 6. EXHIBITS

Exhibit Index:

31.1*		Certification of Interim Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

32.1*		Certification of Interim Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

WORLD HEALTH ENERGY HOLDINGS, INC.
(Registrant)

By:	/s/ Giora Rozensweig
	Giora Rozensweig
	Interim Chief Executive Officer
	(Principal Executive Officer and Principal Financial and Accounting Officer)

Date:	August 14, 2023

EXHIBIT 31.1

RULE 13a-14(a) CERTIFICATION

I, Giora Rozensweig, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023, of World Health Energy Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financing reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2023

/s/ Giora Rozensweig
Giora Rozensweig, Chief Executive Officer
(Principal Executive Officer and Principal Financial
and Accounting Officer)

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

In connection with the Quarterly Report on Form 10-Q of World Health Energy Holdings, Inc. (the “Company”) for the for the fiscal quarter ended June 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, Giora Rozensweig, Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Giora Rozensweig
Giora Rozensweig
Chief Executive Officer (Principal Executive Officer and
Principal Financial and Accounting Officer)

August 14, 2023

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2023	Aug. 14, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-30256
Entity Registrant Name	WORLD HEALTH ENERGY HOLDINGS, INC.
Entity Central Index Key	0000943535
Entity Tax Identification Number	59-2762023
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1825 NW Corporate Blvd. Suite 110
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	(561)
Local Phone Number	870-0440
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		520,796,074,663

Condensed Interim Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 267,151	$ 56,346
Accounts receivable, net	34,413	23,362
Prepaid share based payment to service providers		55,556
Other current assets	83,831	90,991
Total Current assets	448,604	276,508
Right of use asset arising from operating lease	142,272	166,882
Long term prepaid expenses	22,521	23,679
Property and equipment, net	46,756	43,167
Funds in respect of employee rights upon termination	28,373	28,824
Investment in investee (Note 5)	152,766
Intangible assets	9,693,958	9,693,958
Total non-current assets	10,086,646	9,956,510
Total assets	10,535,250	10,233,018
Current Liabilities
Accounts payable	135,379	107,979
Short term operating lease liability	56,432	57,971
Other current liabilities	472,830	621,733
Total current liabilities	664,641	787,683
Non-current Liabilities
Liability for employee rights upon retirement	196,834	180,066
Long term loan from parent company	2,012,339	2,012,339
Long term operating lease liability	69,133	96,102
Deferred tax liability	872,456	872,456
Total current liabilities	3,150,762	3,160,963
Total liabilities	3,815,403	3,948,646
Stockholders’ Equity
Preferred stock, value	3,500	3,500
Common stock, par $0.00001, 750,000,000,000 shares authorized as of June 30, 2023 and December 31, 2022. 520,796,074,663 and 516,302,741,330 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	67,162,651	67,117,718
Additional paid-in capital	(36,194,050)	(40,614,231)
Treasury stock at cost – 20,000,000,000 shares of common stock	(8,000,000)	(8,000,000)
Accumulated other comprehensive loss	(9,095)	(2,611)
Accumulated deficit	(20,027,804)	(16,035,848)
Total Company’s stockholders’ equity	2,935,202	2,468,528
Non-controlling interests	3,784,645	3,815,844
Total stockholders’ equity	6,719,847	6,284,372
Total liabilities and stockholders’ equity	10,535,250	10,233,018
Series A Preferred Stock [Member]
Stockholders’ Equity
Preferred stock, value	3,500	3,500
Related Party [Member]
Current Assets
Related party	63,209	50,253
Other current assets	$ 63,209	$ 50,253

Condensed Interim Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	750,000,000,000	750,000,000,000
Common stock, shares outstanding	520,796,074,663	516,302,741,330
Common stock, shares issued	520,796,074,663	516,302,741,330
Treasury stock, shares	20,000,000,000	20,000,000,000
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0007	$ 0.0007
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares oustanding	5,000,000	5,000,000
Preferred stock, shares issued	5,000,000	5,000,000

Condensed Interim Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenues	$ 102,646	$ 11,212	$ 134,986	$ 43,754
Research and development expenses	(502,187)	(327,838)	(1,005,123)	(451,344)
Selling and marketing expenses	(3,527)		(30,197)
General and administrative expenses	(1,148,382)	(2,458,216)	(3,132,840)	(4,007,344)
Operating loss	(1,551,450)	(2,774,842)	(4,033,174)	(4,414,934)
Finance income, net	10,614	33,338	15,503	36,634
Loss before equity in net loss of equity investments	(1,540,836)	(2,741,504)	(4,017,671)	(4,378,300)
Less: Equity in net gain (loss) of equity investments	250		(227)
Net loss	(1,540,586)	(2,741,504)	(4,017,898)	(4,378,300)
Net - loss attributable to non-controlling interests	12,930		25,942
Net loss attributable to the Company’s stockholders	$ (1,527,656)	$ (2,741,504)	$ (3,991,956)	$ (4,378,300)
Basic net loss per share	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
Diluted net loss per share	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
Weighted average number of shares outstanding used in computing basic and diluted net loss per share	519,297,869,535	491,853,620,450	518,062,280,925	490,672,188,843
Weighted average number of shares outstanding used in computing diluted net loss per share	519,297,869,535	491,853,620,450	518,062,280,925	490,672,188,843
Comprehensive loss:
Net loss	$ (1,540,586)	$ (2,741,504)	$ (4,017,898)	$ (4,378,300)
Other comprehensive loss - Foreign currency translation adjustments	(4,211)		(6,484)
Comprehensive loss	(1,544,797)	(2,741,504)	(4,024,382)	(4,378,300)
Other comprehensive loss attributable to non-controlling interests	(4,041)		(5,257)
Comprehensive loss attributable to the Company’s stockholders	$ (1,535,908)	$ (2,741,504)	$ (4,003,697)	$ (4,378,300)

Condensed Interim Consolidated Statements of Changes in Shareholders' Deficit - USD ($)	Series A Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Proceeds on Account of Shares [Member]	Treasury Stock, Common [Member]	AOCI Including Portion Attributable to Noncontrolling Interest [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 3,500	$ 66,839,685	$ (62,263,494)			$ (5,495)	$ (6,093,450)	$ (1,519,254)		$ (1,519,254)
Beginning balance, shares at Dec. 31, 2021	5,000,000	488,499,407,996
Issuance of shares		$ 28,400	255,600					284,000		284,000
Issuance of shares, shares		2,840,000,000
Share-based payment to employees and services providers			1,310,239					1,310,239		1,310,239
Proceeds on account of shares				290,000				290,000		290,000
Net loss							(1,636,796)	(1,636,796)		(1,636,796)
Ending balance, value at Mar. 31, 2022	$ 3,500	$ 66,868,085	(60,697,655)	290,000		(5,495)	(7,730,246)	(1,271,811)		(1,271,811)
Ending balance, shares at Mar. 31, 2022	5,000,000	491,339,407,996
Beginning balance, value at Dec. 31, 2021	$ 3,500	$ 66,839,685	(62,263,494)			(5,495)	(6,093,450)	(1,519,254)		(1,519,254)
Beginning balance, shares at Dec. 31, 2021	5,000,000	488,499,407,996
Net loss										(4,378,300)
Ending balance, value at Jun. 30, 2022	$ 3,500	$ 66,884,719	(57,929,134)	250,000		(5,495)	(10,471,750)	(1,268,160)		(1,268,160)
Ending balance, shares at Jun. 30, 2022	5,000,000	493,002,741,330
Beginning balance, value at Mar. 31, 2022	$ 3,500	$ 66,868,085	(60,697,655)	290,000		(5,495)	(7,730,246)	(1,271,811)		(1,271,811)
Beginning balance, shares at Mar. 31, 2022	5,000,000	491,339,407,996
Issuance of shares		$ 16,334	310,917	(40,000)				287,250		287,250
Issuance of shares, shares		1,633,333,334
Share-based payment to employees and services providers		$ 300	2,457,605					2,457,905		2,457,905
Net loss							(2,741,504)	(2,741,504)		(2,741,504)
Ending balance, value at Jun. 30, 2022	$ 3,500	$ 66,884,719	(57,929,134)	250,000		(5,495)	(10,471,750)	(1,268,160)		(1,268,160)
Ending balance, shares at Jun. 30, 2022	5,000,000	493,002,741,330
Beginning balance, value at Dec. 31, 2022	$ 3,500	$ 67,117,718	(40,614,231)		(8,000,000)	(2,611)	(16,035,848)	2,468,528	3,815,844	6,284,372
Beginning balance, shares at Dec. 31, 2022	5,000,000	516,302,741,330
Issuance of shares		$ 16,400	512,600					529,000		529,000
Issuance of shares, shares		1,640,000,000
Share-based payment to employees and services providers			2,219,109					2,219,109		2,219,109
Net loss							(2,464,300)	(2,464,300)	(13,012)	(2,477,312)
Other comprehensive loss						(2,273)		(2,273)	(1,216)	(3,489)
Ending balance, value at Mar. 31, 2023	$ 3,500	$ 67,134,118	(37,882,522)		(8,000,000)	(4,884)	(18,500,148)	2,750,064	3,801,616	6,551,680
Ending balance, shares at Mar. 31, 2023	5,000,000	517,942,741,330
Beginning balance, value at Dec. 31, 2022	$ 3,500	$ 67,117,718	(40,614,231)		(8,000,000)	(2,611)	(16,035,848)	2,468,528	3,815,844	6,284,372
Beginning balance, shares at Dec. 31, 2022	5,000,000	516,302,741,330
Net loss										(4,017,898)
Ending balance, value at Jun. 30, 2023	$ 3,500	$ 67,162,651	(36,194,050)		(8,000,000)	(9,095)	(20,027,804)	2,935,202	3,784,645	6,719,847
Ending balance, shares at Jun. 30, 2023	5,000,000	520,796,074,663
Beginning balance, value at Mar. 31, 2023	$ 3,500	$ 67,134,118	(37,882,522)		(8,000,000)	(4,884)	(18,500,148)	2,750,064	3,801,616	6,551,680
Beginning balance, shares at Mar. 31, 2023	5,000,000	517,942,741,330
Issuance of shares		$ 20,833	279,167					300,000		300,000
Issuance of shares, shares		2,083,333,333
Net loss							(1,527,656)	(1,527,656)	(12,930)	(1,540,586)
Other comprehensive loss						(4,211)		(4,211)	(4,041)	(8,252)
Issuance of shares for investment in an investee		$ 7,700	146,300					154,000		154,000
Issuance of shares for investment in an investee, shares		770,000,000
Share-based payment to employees and services providers			1,263,005					1,263,005		1,263,005
Ending balance, value at Jun. 30, 2023	$ 3,500	$ 67,162,651	$ (36,194,050)		$ (8,000,000)	$ (9,095)	$ (20,027,804)	$ 2,935,202	$ 3,784,645	$ 6,719,847
Ending balance, shares at Jun. 30, 2023	5,000,000	520,796,074,663

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (4,017,898)	$ (4,378,300)
Adjustments required to reconcile net loss for the period to net cash used in operating activities:
Depreciation	8,574	4,930
Change in liability for employee rights upon retirement	17,219	(4,667)
Equity in losses of non-consolidated entity	227
Share-based compensation expense	3,537,669	3,945,323
Change in operating lease liability	(3,898)	(19,034)
Change in accounts receivable	(11,051)	(2,411)
Change in other current assets	7,018	8,668
Change in accounts payable	27,399	12,438
Change in other accounts liabilities	(11,939)	(50,120)
Net cash used in operating activities	(446,680)	(483,173)
CASH FLOWS FROM INVESTING ACTIVITIES:
Loans received from (granted to) related parties	(12,843)	7,186
Loan to investee company		(10,000)
Purchase of property and equipment	(12,163)	(13,306)
Net cash used in investing activities	(25,006)	(16,120)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	681,000	611,250
Proceeds on account of shares		250,000
Net cash provided by financing activities	681,000	861,250
Effect of exchange rate changes on cash and cash equivalents	1,491
INCREASE IN CASH AND CASH EQUIVALENTS	210,805	361,957
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	56,346	46,022
CASH AND CASH EQUIVALENTS AT END OF PERIOD	267,151	407
Non cash transactions:
Investment in purchase of subsidiary	154,000
Issuance of share in exchange for debt	$ 144,000

GENERAL

6 Months Ended

Jun. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GENERAL

NOTE 1 – GENERAL

Operations

UCG, INC. (the “UCG”) was incorporated on September 13, 2017, under the laws of the State of Florida. The Company wholly-owns the issued and outstanding shares of RNA Ltd. (“RNA”).

SG Transaction

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL (continue)

CrossMobile Transaction

On July 13, 2022, the Company issued 10,000,000,000 common shares with fair value of $4 million to Crossmobile to consummate the transaction.

The acquisition of the additional 25% constitute an asset acquisition in stages and resulted in obtaining control over all assets of CrossMobile and consolidating CrossMobile as of October 25, 2022.

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL (continue)

Substantially all the consideration were allocated to the license, in addition to $0.9 million costs incurred in connection of the transaction, and hence the license was recognized at $8.8 million.

The Company, collectively with SG, RNA and CrossMobile are hereunder referred to as the “Group”.

InstaView Transaction

Board and Shareholder Authority for Reverse Stock Split

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL (continue)

Liquidity

Since inception, the Company has incurred losses and negative cash flows from operations. The Company has financed its operations mainly through fundraising from various investors.

Risk factors

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Unaudited Interim Financial Statements

Principles of Consolidation

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continue)

Use of Estimates

Investment in investee

COMMON STOCK

6 Months Ended

Jun. 30, 2023

Equity [Abstract]

COMMON STOCK

NOTE 3 – COMMON STOCK

On May 15, 2023, the Company issued 770,000,000 shares of common stock as consideration under InstaView Transaction (see note 1D above).

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

STOCK OPTIONS

6 Months Ended

Jun. 30, 2023

Share-Based Payment Arrangement [Abstract]

STOCK OPTIONS

NOTE 4 - STOCK OPTIONS

The following table presents the Company’s stock option activity during the three and six months ended June 30, 2023:

SCHEDULE OF STOCK OPTION ACTIVITY

	Number of Options		Weighted Average Exercise Price
Outstanding at December 31,2022		46,600,000,000		0.001
Granted		2,000,000		0.001
Exercised		-		-
Forfeited or expired		-		-
Outstanding at March 31,2023		46,602,000,000		0.001
Granted		-		-
Exercised		-		-
Forfeited or expired		-		-
Outstanding at June 30,2023		46,602,000,000		0.001
Number of options exercisable at June 30, 2023		9,600,000,000		0.001

The stock options outstanding as of June 30, 2023, have been separated into exercise prices, as follows:

Exercise price	Stock options outstanding		Weighted average remaining contractual life – years		Stock options vested
	As of June 30, 2023
0.001		46,602,000,000		3.26		17,525,000,000
		46,602,000,000		3.26		17,525,000,000

The stock options outstanding as of June 30, 2022, have been separated into exercise prices, as follows:

Exercise price	Stock options outstanding		Weighted average remaining contractual life – years		Stock options vested
	As of June 30, 2022
0.001		13,200,000,000		3.55		-
		13,200,000,000		3.55		-

WORLD HEALTH ENERGY HOLDINGS, INC .

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

EQUITY METHOD INVESTMENTS IN UNCONSOLIDATED AFFILIATES

6 Months Ended

Jun. 30, 2023

Equity Method Investments and Joint Ventures [Abstract]

EQUITY METHOD INVESTMENTS IN UNCONSOLIDATED AFFILIATES

NOTE 5 - EQUITY METHOD INVESTMENTS IN UNCONSOLIDATED AFFILIATES

The following tables summarize the carrying amounts, including changes therein, of our equity method investment in InstaView during the period:

SCHEDULE OF EQUITY METHOD INVESTMENT

	Six months ended June 30, 2023

Opening balance	$	-
Equity investment		91,917
Other comprehensive loss		(1,007	)
Equity losses		(227	)
Investments under equity method.		90,683
Purchased Option		62,083
Investment in investee as of June 30, 2023	$	152,766

RELATED PARTIES

6 Months Ended

Jun. 30, 2023

RELATED PARTIES

NOTE 6 – RELATED PARTIES

SCHEDULE OF RELATED PARTY EXPENSES

Transactions and balances with related parties

	2023		2022		2023		2022
	Six months ended June 30				Three months ended June 30
	2023		2022		2023		2022
	(Unaudited)		(Unaudited)		(Unaudited)		(Unaudited)

General and administrative expenses:
Salaries and fees to officers		1,420,162		2,028,654		613,219		1,067,882
(*) of which share based compensation		1,329,597		1,943,090		573,520		1,023,625

Research and development expenses:
Salaries and fees to officers		137,213		69,723		59,402		46,308
(*) of which share based compensation		91,483		26,040		39,504		26,040

Balances with related parties and officers:

	As of June 30,		As of December 31,
	2023		2022
		(Unaudited)		(Audited)

Other current assets		63,209		50,253
Other accounts liabilities		103,311		-
Liability for employee rights upon retirement		123,723		229,167
Long term loan from related party (*)		2,012,339		2,012,339

(*)	Received from UCG by December 31, 2021. The loan bears no interest.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Unaudited Interim Financial Statements	Unaudited Interim Financial Statements The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiary, prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions to Form 10-Q. In the opinion of management, the financial statements presented herein have not been audited by an independent registered public accounting firm but include all material adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the financial condition, results of operations and cash flows for the six-months ended June 30, 2023. However, these results are not necessarily indicative of results for any other interim period or for the year ended December 31, 2023. The preparation of financial statements in conformity with GAAP requires the Company to make certain estimates and assumptions for the reporting periods covered by the financial statements. These estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses. Actual amounts could differ from these estimates. Certain information and footnote disclosures normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on published on the OTCIQ, for the year ended December 31, 2022.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements are prepared in accordance with GAAP. The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All inter-company balances and transactions have been eliminated. WORLD HEALTH ENERGY HOLDINGS, INC . NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continue)
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, certain revenues and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates.
Investment in investee	Investment in investee The Company accounts of its options in InstaView in accordance with ASC 321, Investments – Equity Securities. The Company elected the measurement alternative under which the options are measured at cost as they have no readily determinable fair value. The carrying amount of the investment is included within Investment in investee, non-current assets in the Consolidated Balance Sheets. The equity securities will be carried at cost less impairment, if any, and subsequently measured to fair value upon observable price changes in an orderly transaction for the identical or similar investments with any gains or losses recorded to the consolidated statement of operations and comprehensive income

STOCK OPTIONS (Tables)

6 Months Ended

Jun. 30, 2023

Share-Based Payment Arrangement [Abstract]

SCHEDULE OF STOCK OPTION ACTIVITY

The following table presents the Company’s stock option activity during the three and six months ended June 30, 2023:

SCHEDULE OF STOCK OPTION ACTIVITY

	Number of Options		Weighted Average Exercise Price
Outstanding at December 31,2022		46,600,000,000		0.001
Granted		2,000,000		0.001
Exercised		-		-
Forfeited or expired		-		-
Outstanding at March 31,2023		46,602,000,000		0.001
Granted		-		-
Exercised		-		-
Forfeited or expired		-		-
Outstanding at June 30,2023		46,602,000,000		0.001
Number of options exercisable at June 30, 2023		9,600,000,000		0.001

SCHEDULE OF STOCK OPTIONS OUTSTANDING RANGE OF EXERCISE PRICE

The stock options outstanding as of June 30, 2023, have been separated into exercise prices, as follows:

Exercise price	Stock options outstanding		Weighted average remaining contractual life – years		Stock options vested
	As of June 30, 2023
0.001		46,602,000,000		3.26		17,525,000,000
		46,602,000,000		3.26		17,525,000,000

The stock options outstanding as of June 30, 2022, have been separated into exercise prices, as follows:

Exercise price	Stock options outstanding		Weighted average remaining contractual life – years		Stock options vested
	As of June 30, 2022
0.001		13,200,000,000		3.55		-
		13,200,000,000		3.55		-

EQUITY METHOD INVESTMENTS IN UNCONSOLIDATED AFFILIATES (Tables)

6 Months Ended

Jun. 30, 2023

Equity Method Investments and Joint Ventures [Abstract]

SCHEDULE OF EQUITY METHOD INVESTMENT

The following tables summarize the carrying amounts, including changes therein, of our equity method investment in InstaView during the period:

SCHEDULE OF EQUITY METHOD INVESTMENT

	Six months ended June 30, 2023

Opening balance	$	-
Equity investment		91,917
Other comprehensive loss		(1,007	)
Equity losses		(227	)
Investments under equity method.		90,683
Purchased Option		62,083
Investment in investee as of June 30, 2023	$	152,766

RELATED PARTIES (Tables)

6 Months Ended

Jun. 30, 2023

SCHEDULE OF RELATED PARTY EXPENSES

Transactions and balances with related parties

	2023		2022		2023		2022
	Six months ended June 30				Three months ended June 30
	2023		2022		2023		2022
	(Unaudited)		(Unaudited)		(Unaudited)		(Unaudited)

General and administrative expenses:
Salaries and fees to officers		1,420,162		2,028,654		613,219		1,067,882
(*) of which share based compensation		1,329,597		1,943,090		573,520		1,023,625

Research and development expenses:
Salaries and fees to officers		137,213		69,723		59,402		46,308
(*) of which share based compensation		91,483		26,040		39,504		26,040

Balances with related parties and officers:

	As of June 30,		As of December 31,
	2023		2022
		(Unaudited)		(Audited)

Other current assets		63,209		50,253
Other accounts liabilities		103,311		-
Liability for employee rights upon retirement		123,723		229,167
Long term loan from related party (*)		2,012,339		2,012,339

(*)	Received from UCG by December 31, 2021. The loan bears no interest.

GENERAL (Details Narrative) - USD ($)								3 Months Ended				6 Months Ended
GENERAL (Details Narrative) - USD ($)	May 17, 2023	Jan. 26, 2023	Oct. 25, 2022	Jul. 13, 2022	Mar. 22, 2022	Dec. 03, 2021	Apr. 27, 2020	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Dec. 31, 2022	Nov. 01, 2022	Oct. 07, 2021	Oct. 06, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock shares authorized								750,000,000,000				750,000,000,000	750,000,000,000
Common stock par value								$ 0.00001				$ 0.00001	$ 0.00001
New issuance, value								$ 300,000	$ 529,000	$ 287,250	$ 284,000
Shares issued, exercised
Acquisition Cost Ratio												26.00%
Treasury stock, common shares								20,000,000,000				20,000,000,000	20,000,000,000
Noncontrolling interest								$ 3,784,645				$ 3,784,645	$ 3,815,844
License cost			$ 900,000
Recognized license cost			8,800,000
Deferred tax liabilities			872,000
Business combination tax basis			0
Allocated amount related to purchase option												62,083
Reverse stock split	Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation (“Reverse Stock Split Certificate of Amendment”) in order to effect a reverse stock split of the Company’s common stock pursuant to a range of between 20,000-to-1 and 60,000-to-1 (the “Reverse Stock Split”), when and as determined by the Company’s Board of Directors. Pursuant to the Reverse Stock Split, each twenty thousand or sixty thousand shares of common stock, or any other figure within that range, as shall be determined by the Board of Directors at a later time, will be automatically converted, without any further action by the stockholders, into one share of common stock. The Reverse Stock Split Certificate of Amendment will be effective upon receipt of approval from the Financial Industry Regulatory Authority (“FINRA”) for the Reverse Stock Split and the filing with the Secretary of the State of Delaware. As of the date of this report, the Board of Directors has not determined any particular range for the Reverse Stock Split and no application has been presented to FINRA
Investment								3,000,000				3,000,000
Subscriptions receivable amount								$ 625,000				$ 625,000
Cross Mobile [Member] \| License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity method investment percent								90.00%				90.00%
Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock par value																$ 0.0007
Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued								2,083,333,333	1,640,000,000	1,633,333,334	2,840,000,000
Common stock shares authorized															750,000,000,000	110,000,000,000
Common stock par value															$ 0.00001
New issuance, value								$ 20,833	$ 16,400	$ 16,334	$ 28,400
UCG, INC. [Member] \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares, conversion						387,000,000,000
Insta View Ltd [Member] \| Common Stock [Member] \| Investment Agreement [Member] \| 2023 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity method investment percent		7.00%
Sale of stock, number of shares issued in transaction		207,307,692
Insta View Ltd [Member] \| Common Stock [Member] \| Investment Agreement [Member] \| 2024 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity method investment percent		8.00%
Sale of stock, number of shares issued in transaction		236,923,077
Insta View Ltd [Member] \| Common Stock [Member] \| Investment Agreement [Member] \| 2025 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity method investment percent		10.00%
Sale of stock, number of shares issued in transaction		296,153,846
Series B Preferred Stock [Member] \| UCG, INC. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares, conversion						3,870,000
Merger Agreement [Member] \| Series B Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares converted							100,000
Number of common stock issued on conversion							387,000,000,000
Merger Agreement [Member] \| Series B Preferred Stock [Member] \| UCG, INC. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued							3,870,000
Preferred stock, par value							$ 0.0007
Cross Mobile Investment Agreement [Member] \| Giora Rosenzweig [Member] \| Cross Mobbnile [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity method investment percent					40.67%
Cross Mobile Investment Agreement [Member] \| George Baumoehl [Member] \| Cross Mobbnile [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity method investment percent					3.33%
Cross Mobile Investment Agreement [Member] \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock outstanding, rate					26.00%
Restricted number of shares issued				10,000,000,000	10,000,000,000
New issuance, value				$ 4,000,000
Noncontrolling interest			$ 7,900,000
Cross Mobile Investment Agreement [Member] \| Common Stock [Member] \| Cross Mobile [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued			20,000,000,000
New issuance, value			$ 8,000,000
Percentage of hold outstanding share capital on fullly diluted basis			51.00%
Asset acquisition, percentage			25.00%
Shares issued, exercised			10,000,000
Shares issued, per share			$ 0.0004
Treasury stock, common shares			20,000,000,000
Noncontrolling interest, rate			49.00%
Cross Mobile Investment Agreement [Member] \| Common Stock [Member] \| Minimum [Member] \| Cross Mobile [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock outstanding, rate			26.00%
Cross Mobile Investment Agreement [Member] \| Common Stock [Member] \| Maximum [Member] \| Cross Mobile [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock outstanding, rate			51.00%
Investment Agreement [Member] \| Insta View Ltd [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity method investment percent		26.00%
Investment Agreement [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment														$ 3,000,000
Investment Agreement [Member] \| Insta View Ltd [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Restricted number of shares issued		770,000,000
Equity investment, assets		$ 154,000
Allocated amount related to purchase option		$ 62,083
Investment Agreement [Member] \| Insta View Ltd [Member] \| Restricted Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Restricted number of shares issued		770,000,000
Investment Agreement [Member] \| IstaView Ltd [Member] \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued		230,000,000

COMMON STOCK (Details Narrative) - USD ($)				3 Months Ended				6 Months Ended
COMMON STOCK (Details Narrative) - USD ($)	Jun. 30, 2023	May 05, 2023	Feb. 08, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	May 15, 2023
Subsidiary, Sale of Stock [Line Items]
Proceeds from common stock								$ 681,000	$ 611,250
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued				2,083,333,333	1,640,000,000	1,633,333,334	2,840,000,000
Common Stock [Member] \| Insta View [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued										770,000,000
Common Stock [Member] \| Director [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of price per share	$ 0.0003	$ 0.0003		$ 0.0003				$ 0.0003
Shares issued	2,083,333,333	2,083,333,333		2,083,333,333				2,083,333,333
Proceeds from common stock	$ 625,000	$ 625,000
Common Stock [Member] \| Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued			1,440,000,000
Principal amount			$ 120,000
Accrued interest			$ 24,000
Debt instrument term			10 years
Private Placement [Member] \| Common Stock [Member] \| Investment Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance of private placement			$ 60,000
Sale of price per share			$ 0.0003
Number of shares issued			200,000,000

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Number of options outstanding beginning balance	46,602,000,000	46,600,000,000
Weighted average exercise price, outstanding, beginning balance	$ 0.001	$ 0.001
Number of options, granted		2,000,000
Weighted average exercise price, granted		$ 0.001
Number of options, exercised
Weighted average exercise price, exercised
Number of options, forfeited or expired
Weighted average exercise price, forfeited or expired
Number of options outstanding ending balance	46,602,000,000	46,602,000,000
Weighted average exercise price, outstanding, ending balance	$ 0.001	$ 0.001
Number of options exercisable	9,600,000,000
Weighted average exercise price, number of option exercisable	$ 0.001

SCHEDULE OF STOCK OPTIONS OUTSTANDING RANGE OF EXERCISE PRICE (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Offsetting Assets [Line Items]
Number outstanding, options outstanding	46,602,000,000	13,200,000,000
Weighted average remaining contractual life-years, options outstanding	3 years 3 months 3 days	3 years 6 months 18 days
Weighted average remaining contractual life-years, options outstanding	17,525,000,000
Exercise Price Range One [Member]
Offsetting Assets [Line Items]
Exercise price	$ 0.001	$ 0.001
Number outstanding, options outstanding	46,602,000,000	13,200,000,000
Weighted average remaining contractual life-years, options outstanding	3 years 3 months 3 days	3 years 6 months 18 days
Weighted average remaining contractual life-years, options outstanding	17,525,000,000

STOCK OPTIONS (Details Narrative) - USD ($)		6 Months Ended
STOCK OPTIONS (Details Narrative) - USD ($)	Jan. 26, 2023	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Aggregate intrinsic value outstanding		$ 0
Share price per share		$ 0.0001
Option to purchase of shares	1,000,000,000
Exercise price	$ 0.0002
Exercisable period	4 years
Option to vest, shares	250,000,000
Fair value of options	$ 563,230
Risk free rate	3.72%
Volatility factor	186.71%
Dividend yields	0.00%
Expected life	4 years
Share based compensation		$ 3,537,669	$ 3,945,323
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation		3,537,670
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation		$ 110,006

SCHEDULE OF EQUITY METHOD INVESTMENT (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Opening balance
Equity investment			91,917
Other comprehensive loss			(1,007)
Equity losses	$ 250		(227)
Investments under equity method.			90,683
Purchased Option			62,083
Investment in investee as of June 30, 2023	$ 152,766		$ 152,766